Product/Composition:- | Cotrimoxazole tablets |
---|---|
Strength:- | 80 mg trimethoprim / 400 mg sulfamethoxazole |
Form:- | Tablets |
Reference Brands:- | Bactrim, Septra(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Cotrimoxazole tablets combine trimethoprim and sulfamethoxazole to inhibit bacterial folic acid synthesis, preventing DNA replication. It effectively treats urinary, respiratory, and skin infections. Benefits include broad-spectrum antibacterial activity, symptom relief, decreased infection transmission, and support for effectively managing urinary, respiratory, and skin bacterial infections.
Cotrimoxazole tablets, marketed as Bactrim and Septra, are approved in the US by the FDA and in the EU via EMA for treating bacterial infections including urinary tract, respiratory, and skin infections. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews clinical trial and quality data, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional requirements supports timely approval, safe use, and worldwide availability of cotrimoxazole tablets, ensuring effective antibacterial therapy for patients across the globe.